Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

Source Summary

Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.